/person/andrews-ron-ronnie-life-technologies-corporation-thermo-fisher-2001-3131.html

Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px
Person › Details

Ron A. (Ronnie) Andrews (Life Technologies Corporation)

Andrews, Ron A. (Ronnie) (Life Technologies 201202– President Medical Sciences before GE Healthcare + CEO of Clarient)

 

Organisations Organisation Life Technologies Corporation
  Today Thermo Fisher Scientific Inc., Carlsbad, CA (Life Technologies business)
  Group Thermo Fisher (Group)
  Former/major organisation Clarient Inc. (Nasdaq: CLRT)
  Group General Electric (Group)
Product Product diagnostics (medical/biological)
     

Definiens AG. (3/26/13). "Press Release: Definiens Establishes Advisory Board. Renowned Industry Experts to Advise Definiens on Clinical Digital Pathology Market". Munich.

Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, today announced it has appointed an Advisory Board comprising renowned industry experts and visionaries in digital pathology. As part of its market expansion strategy, Definiens established the new Board to provide independent advice on trends and opportunities in tissue diagnostics and clinical digital pathology.

Members of the Advisory Board include:

> Ron A. Andrews, President, Medical Sciences, Life Technologies and former CEO of Clarient and CEO of GE Molecular Diagnostics

> Prof. Uwe Bicker, Dean of the Medical Faculty Mannheim, University of Heidelberg and a member of the board of directors of Sanofi SA

> Prof. Manfred Dietel, Director, Institute of Pathology, Charité Berlin and chairman of the German Society for Pathology

> Eric F. Glassy, M.D., Medical Director, Pathology, Inc.and chairman of the Digital Pathology Working Group of the College of American Pathologists

> Prof. Gerd Binnig, Founder and CTO, Definiens (Moderator)


"Definiens is working to advance personalized medicine by contributing to the development of next generation diagnostics, and bringing those novel diagnostics into clinical practice. Our innovations have the potential to transform daily clinical practice for the benefit of both patients and pathologists, particularly in oncology," said Thomas Heydler, CEO of Definiens. "We will greatly benefit from the wealth of experience of the Advisory Board members while expanding our business into tissue diagnostics and clinical digital pathology."

As part of its goal to guide Definiens during the company's expansion, the Advisory Board will discuss trends in digital pathology and highlight opportunities for image and data analysis to revolutionize clinical practice in pathology. Specific topics of discussion will include pathology workflow, tissue diagnostic test development, personalized medicine and next-generation cancer treatment, as well as future technology and market requirements. Definiens founder and Nobel laureate, Professor Gerd Binnig, will catalyze the discussions.

"With the novel opportunities enabled by digital pathology, progress in diagnosing and treating cancer will be accelerated. The visionary power and expertise brought together in the Definiens Advisory Board will be invaluable on our path towards bringing advanced image analysis to clinical pathology," said Prof. Gerd Binnig, Founder and CTO of Definiens.


About Definiens

Definiens is the leading provider of image analysis and data mining solutions for life sciences, tissue diagnostics and clinical digital pathology. Definiens software provides detailed cell-by-cell readouts from target structures on whole tissue slides, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens' vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients' lives.
Definiens is headquartered in Munich, Germany and has offices throughout the United States.


Media Contact

Definiens AG
Dr Florian Leiss
Manager Marketing Communications
+49 (89) 2311-8024
fleiss@definiens.com

   
Record changed: 2017-04-09

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px


More documents for Ron A. (Ronnie) Andrews


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px




» top